ErbB Receptors: from Oncogenes to Targeted Cancer Therapies

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2007 Aug 3

PMID 17671639

Citations 240

Authors

Hongtao Zhang

Alan Berezov

Qiang Wang

Geng Zhang

Jeffrey Drebin

Ramachandran Murali

Mark I Greene

Affiliations

Soon will be listed here.

Abstract

Understanding the genetic origin of cancer at the molecular level has facilitated the development of novel targeted therapies. Aberrant activation of the ErbB family of receptors is implicated in many human cancers and is already the target of several anticancer therapeutics. The use of mAbs specific for the extracellular domain of ErbB receptors was the first implementation of rational targeted therapy. The cytoplasmic tyrosine kinase domain is also a preferred target for small compounds that inhibit the kinase activity of these receptors. However, current therapy has not yet been optimized, allowing for opportunities for optimization of the next generation of targeted therapy, particularly with regards to inhibiting heteromeric ErbB family receptor complexes.

Citing Articles

HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions.

Camera S, Rossari F, Foti S, Vitiello F, Persano M, Prinzi F Target Oncol. 2025; .

PMID: 39985696 DOI: 10.1007/s11523-025-01132-w.

Metformin inhibits the growth of SCLC cells by inducing autophagy and apoptosis via the suppression of EGFR and AKT signalling.

Xia H, Tai X, Cheng W, Wu Y, He D, Wang L Sci Rep. 2025; 15(1):6081.

PMID: 39971923 PMC: 11839993. DOI: 10.1038/s41598-025-87537-z.

Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension-A Systematic Review.

Jasinska-Stroschein M, Glajzner P Int J Mol Sci. 2024; 25(23).

PMID: 39684570 PMC: 11641621. DOI: 10.3390/ijms252312858.

Targeting erbB Pathways in Breast Cancer: Dual Kinase Inhibition for Brain Metastasis and Prevention of p185HER2/Neu Tumor Development.

Goel P, Katsumata M, Qian W, Mathur S, Ji M, Samanta A Breast Cancer (Dove Med Press). 2024; 16:725-733.

PMID: 39493351 PMC: 11531735. DOI: 10.2147/BCTT.S490904.

Leucine-Rich Alpha-2-Glycoprotein 1 Promotes Metastatic Colorectal Cancer Growth Through Human Epidermal Growth Factor Receptor 3 Signaling.

Rathore M, Curry K, Huang W, Wright M, Martin D, Baek J Gastroenterology. 2024; 168(2):300-315.e3.

PMID: 39393543 PMC: 11769768. DOI: 10.1053/j.gastro.2024.10.004.

References

Yoshimura N, Kudoh S, Kimura T, Mitsuoka S, Matsuura K, Hirata K . EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer. 2005; 51(3):363-8. DOI: 10.1016/j.lungcan.2005.10.006. View

Schechter A, Stern D, Vaidyanathan L, Decker S, Drebin J, Greene M . The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984; 312(5994):513-6. DOI: 10.1038/312513a0. View

Montagna C, Andrechek E, Padilla-Nash H, Muller W, Ried T . Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene. 2002; 21(6):890-8. DOI: 10.1038/sj.onc.1205146. View

Campos S, Hamid O, Seiden M, Oza A, Plante M, Potkul R . Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol. 2005; 23(24):5597-604. DOI: 10.1200/JCO.2005.08.091. View

Spiridon C, Guinn S, Vitetta E . A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res. 2004; 10(10):3542-51. DOI: 10.1158/1078-0432.CCR-03-0549. View

van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R . Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987; 7(5):2019-23. PMC: 365313. DOI: 10.1128/mcb.7.5.2019-2023.1987. View

Nahta R, Yuan L, Zhang B, Kobayashi R, Esteva F . Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65(23):11118-28. DOI: 10.1158/0008-5472.CAN-04-3841. View

McGuire W . Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat. 1987; 10(1):5-9. DOI: 10.1007/BF01806129. View

RUDKIN C, HUNGERFORD D, Nowell P . DNA CONTENTS OF CHROMOSOME PH1 AND CHROMOSOME 21 IN HUMAN CHRONIC GRANULOCYTIC LEUKEMIA. Science. 1964; 144(3623):1229-31. DOI: 10.1126/science.144.3623.1229. View

10.

Xia W, Husain I, Liu L, Bacus S, Saini S, Spohn J . Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res. 2007; 67(3):1170-5. DOI: 10.1158/0008-5472.CAN-06-2101. View

11.

Plowman G, Culouscou J, Whitney G, Green J, Carlton G, Foy L . Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A. 1993; 90(5):1746-50. PMC: 45956. DOI: 10.1073/pnas.90.5.1746. View

12.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

13.

Tan M, Lan K, Yao J, Lu C, Sun M, Neal C . Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res. 2006; 66(7):3764-72. DOI: 10.1158/0008-5472.CAN-05-2747. View

14.

Weiner D, Liu J, Cohen J, Williams W, Greene M . A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature. 1989; 339(6221):230-1. DOI: 10.1038/339230a0. View

15.

Wada T, Qian X, Greene M . Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell. 1990; 61(7):1339-47. DOI: 10.1016/0092-8674(90)90697-d. View

16.

Slamon D, Romond E, Perez E . Advances in adjuvant therapy for breast cancer. Clin Adv Hematol Oncol. 2006; 4(3 Suppl 7):suppl 1, 4-9. View

17.

Qian X, LeVea C, Freeman J, Dougall W, Greene M . Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Proc Natl Acad Sci U S A. 1994; 91(4):1500-4. PMC: 43187. DOI: 10.1073/pnas.91.4.1500. View

18.

Rowley J . Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243(5405):290-3. DOI: 10.1038/243290a0. View

19.

Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J . Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007; 99(8):628-38. DOI: 10.1093/jnci/djk134. View

20.

Rusnak D, Affleck K, Cockerill S, Stubberfield C, Harris R, Page M . The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001; 61(19):7196-203. View